Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity.
5 affiliations
- 1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
- 2Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA 30329, USA.
- 3Molecular and Systems Pharmacology Graduate Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA.
- 4Cancer Biology Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, Atlanta, GA 30322, USA.
- 5Department of Pathology, Children's Healthcare of Atlanta, Atlanta, GA 30329, USA.
Abstract
Background
Acute myeloid leukemia (AML) remains the deadliest form of leukemia in children and adults despite therapeutic advances in recent decades. Chimeric antigen receptor (CAR) T-cell therapy is one such therapeutic approach that has been explored preclinically and clinically in AML; however, its efficacy is limited by antigen heterogeneity. To overcome this roadblock, we propose a dual-targeting CAR T-cell strategy, targeting the AML-associated antigens CD33 and CD70.Methods
To recapitulate tumor heterogeneity, we genetically edited the AML cell line Molm-13 using CRISPR-Cas9 to generate distinct sublines, namely CD33+/CD70-, CD33-/CD70+, and CD33+/CD70+. Two dual-targeting CAR T-cell approaches were developed: a "pooled" product, in which CAR T cells directed towards CD33 or CD70 are combined and co-administered, and a "co-transduced" product, wherein one population of T cells is transduced with both CD33-CAR- and CD70-CAR-encoding viral vectors.Results
Pooled and co-transduced products demonstrated potent cytotoxicity against all Molm-13 populations, whereas single-antigen CAR approaches were not as effective when their respective target antigen was absent. Mice engrafted with CD33/CD70 heterogeneous Molm-13 cells were treated with pooled or co-transduced CD33/CD70 CAR T cells. Both groups exhibited a significant survival advantage over the untreated group, with the co-transduced approach showing a statistically significant advantage over the pooled group.Conclusions
In summary, engineering one T cell to express both CARs yielded superior cytotoxicity when targeting a heterogeneous AML blast population.
Related
- Targeting the Tumor Microenvironment Network to Overcome Immunotherapy Resistance in Non‐Small Cell Lung Cancer: Mechanisms to Clinical Translation
- Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.
- Targeting post-translational modifications to overcome glioblastoma therapy resistance: emerging strategies and natural compounds
- Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance
- A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma
BibTeX
@article{sullivan2026developing,
title = {{Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity.}},
author = {Emily C Sullivan and Nabil Saleem and Areeba A Hashmi and Kristopher A Knight and Austre Y Schiaffino Bustamante and Ahmed A Aljudi and Brandon J Fanelli and Sunil S Raikar},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18193183},
url = {https://europepmc.org/article/MED/42882877},
note = {CC BY},
}
RIS
TY - JOUR
TI - Developing a Dual-Targeting CD33/CD70 CAR T-Cell Strategy Against Acute Myeloid Leukemia to Overcome Tumor Heterogeneity.
AU - Emily C Sullivan
AU - Nabil Saleem
AU - Areeba A Hashmi
AU - Kristopher A Knight
AU - Austre Y Schiaffino Bustamante
AU - Ahmed A Aljudi
AU - Brandon J Fanelli
AU - Sunil S Raikar
PY - 2026
DA - 2026/10/02
JO - Cancers
DO - 10.3390/cancers18193183
UR - https://europepmc.org/article/MED/42882877
AB - Background Acute myeloid leukemia (AML) remains the deadliest form of leukemia in children and adults despite therapeutic advances in recent decades. Chimeric antigen receptor (CAR) T-cell therapy is one such therapeutic approach that has been explored preclinically and clinically in AML; however, its efficacy is limited by antigen heterogeneity. To overcome this roadblock, we propose a dual-targeting CAR T-cell strategy, targeting the AML-associated antigens CD33 and CD70.Methods To recapitulate tumor heterogeneity, we genetically edited the AML cell line Molm-13 using CRISPR-Cas9 to generate distinct sublines, namely CD33+/CD70-, CD33-/CD70+, and CD33+/CD70+. Two dual-targeting CAR T-cell approaches were developed: a "pooled" product, in which CAR T cells directed towards CD33 or CD70 are combined and co-administered, and a "co-transduced" product, wherein one population of T cells is transduced with both CD33-CAR- and CD70-CAR-encoding viral vectors.Results Pooled and co-transduced products demonstrated potent cytotoxicity against all Molm-13 populations, whereas single-antigen CAR approaches were not as effective when their respective target antigen was absent. Mice engrafted with CD33/CD70 heterogeneous Molm-13 cells were treated with pooled or co-transduced CD33/CD70 CAR T cells. Both groups exhibited a significant survival advantage over the untreated group, with the co-transduced approach showing a statistically significant advantage over the pooled group.Conclusions In summary, engineering one T cell to express both CARs yielded superior cytotoxicity when targeting a heterogeneous AML blast population.
SN - 2072-6694
ER -